Overview

Combination of Ibrutinib and As2O3 in the Treatment of CLL

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the combination of As2O3 and ibrutinib is synergistic in chronic lymphocytic leukemia
Phase:
Phase 3
Details
Lead Sponsor:
Peking University People's Hospital
Collaborator:
Beijing Hospital
Treatments:
Arsenic Trioxide